PedAM
Pediatric Disease Annotations & Medicines
| rhinitis | ||||
| Disease ID | 713 |
|---|---|
| Disease | rhinitis |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:13) C0004096 | asthma | 149 C0002111 | allergy | 19 C0037199 | sinusitis | 10 C0231918 | nasal symptoms | 9 C0422833 | ent symptoms | 6 C0009450 | infection | 5 C0004096 | bronchial asthma | 4 C0010200 | cough | 4 C0085129 | bronchial hyperreactivity | 4 C0003467 | anxiety | 4 C0264423 | occupational asthma | 1 C0027424 | nasal congestion | 1 C0001883 | airways obstruction | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:2) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs324011 | 22017802 | 6915 | TBXA2R | umls:C0035455 | BeFree | However, an association between rs324011 in STAT6 with recurrent wheezing in early childhood and a suggestive association between rs8113232 in TBXA2R with rhinitis in children with asthma were observed. | 0.120271442 | 2012 | STAT6 | 12 | 57108399 | C | T |
| rs8113232 | 22017802 | 6915 | TBXA2R | umls:C0035455 | BeFree | However, an association between rs324011 in STAT6 with recurrent wheezing in early childhood and a suggestive association between rs8113232 in TBXA2R with rhinitis in children with asthma were observed. | 0.120271442 | 2012 | GIPC3 | 19 | 3586545 | G | A |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:8) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0035455 | capsaicin | D002211 | 404-86-4 | rhinitis | MESH:D012220 | marker/mechanism | 19672097 | ||
| C0035455 | cetirizine | D017332 | 83881-51-0 | rhinitis | MESH:D012220 | therapeutic | 12167471 | ||
| C0035455 | fluoxetine | D005473 | 54910-89-3 | rhinitis | MESH:D012220 | marker/mechanism | 2071559 | ||
| C0035455 | hydroxyzine | D006919 | 68-88-2 | rhinitis | MESH:D012220 | therapeutic | 19672097 | ||
| C0035455 | montelukast | C093875 | 158966-92-8 | rhinitis | MESH:D012220 | therapeutic | 20332717 | ||
| C0035455 | triprolidine | D014311 | 486-12-4 | rhinitis | MESH:D012220 | therapeutic | 1098524 | ||
| C0035455 | zafirlukast | C062735 | 107753-78-6 | rhinitis | MESH:D012220 | therapeutic | 12742009 | ||
| C0035455 | zidovudine | D015215 | 30516-87-1 | rhinitis | MESH:D012220 | marker/mechanism | 9089033 | ||
FDA approved drug and dosage information(Total Drugs:6) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D012220 | retrovir | zidovudine | 100MG | CAPSULE;ORAL | Prescription | AB | Yes | Yes |
| MESH:D012220 | retrovir | zidovudine | 50MG/5ML | SYRUP;ORAL | Prescription | AA | Yes | Yes |
| MESH:D012220 | retrovir | zidovudine | 10MG/ML | INJECTABLE;INJECTION | Prescription | AP | Yes | Yes |
| MESH:D012220 | retrovir | zidovudine | 200MG | TABLET;ORAL | Discontinued | None | No | No |
| MESH:D012220 | zidovudine | zidovudine | 60MG | TABLET;ORAL | Discontinued | None | No | No |
| MESH:D012220 | zidovudine | zidovudine | 60MG | TABLET;ORAL | Discontinued | None | No | No |
FDA labeling changes(Total Drugs:6) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D012220 | 6/11/2009 | retrovir | zidovudine | Treatment of HIV-1 infection in combination with other antiretroviral agents | Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |
| MESH:D012220 | 6/11/2009 | retrovir | zidovudine | Treatment of HIV-1 infection in combination with other antiretroviral agents | Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |
| MESH:D012220 | 6/11/2009 | retrovir | zidovudine | Treatment of HIV-1 infection in combination with other antiretroviral agents | Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |
| MESH:D012220 | 6/11/2009 | retrovir | zidovudine | Treatment of HIV-1 infection in combination with other antiretroviral agents | Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |
| MESH:D012220 | 09/19/2008 | retrovir syrup, capsules and tablets | zidovudine | Used in combination with 18 other antiretroviral agents for the treatment of HIV-1 infection | Dosing and administration information provided to children 6 weeks to less than 18 years of age Macrocytosis was reported in the majority of pediatric patients receiving Retrovir 180 mg/m2 every 6 hours in open-label studies New dosing regimen | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |
| MESH:D012220 | 6/11/2009 | retrovir | zidovudine | Treatment of HIV-1 infection in combination with other antiretroviral agents | Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |